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Abstract: The NLRP3 inflammasome controls IL-1β maturation in antigen presenting cells but a 
direct role for NLRP3 in human adaptive immune cells has not been described. Here we show 
that the NLRP3 inflammasome assembles in human CD4+ T cells and initiates caspase-1-
dependent IL-1β secretion, thereby promoting IFN-γ production and Th1 differentiation in an 
autocrine fashion. Importantly, NLRP3 assembly requires intracellular C5 activation and 
stimulation of C5a receptor 1 (C5aR1), which is controlled by surface-expressed C5aR2. 
Dysregulation of NLRP3 activity in T cells affects inflammatory responses in autoimmune 
disease and infection. First, CD4+ T cells from patients with cryopyrin-associated periodic 
syndromes (CAPS), who have constitutively-active NLRP3, exhibit overactive Th1 responses 
that are normalized by NLRP3 inhibitor treatment. Second, IFN-γ production is impaired in T 
cells from Nlpr3–/– mice upon viral infection and alters disease outcome in a colitis model. Our 
results demonstrate that NLRP3 inflammasome activity is not confined to ‘innate immune cells’ 
but is an integral component of normal adaptive Th1 responses.  
 
One Sentence Summary: Non-canonical complement activation in T cells regulates intrinsic 
NLRP3 inflammasome activity and IFN-γ production.   
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Main Text: The complement system is an ancient innate immune sensor system and essential for 
the elimination of pathogens by the host. Processing in serum of liver-derived C3 into C3a and 
C3b and of C5 into C5a and C5b activation fragments leads to opsonization and removal of 
invading microbes, mobilization of innate immune cells, and induction of inflammatory reactions 
(1). However, complement also profoundly regulates adaptive immunity: in addition to T cell 
receptor (TCR) activation, co-stimulation and the presence of interleukin (IL)-12 (2), human 
CD4+ T cells also depend on activation of T cell-expressed complement receptors for normal 
Th1 induction (3). In particular, C3a and C3b are generated intracellularly via cathepsin L-
mediated cleavage of C3 in T cells upon TCR activation (4). These engage their respective 
receptors, the G-protein coupled receptor (GPCR) C3a receptor (C3aR) and the complement 
regulator CD46 (which binds C3b), and induce autocrine IFN-γ (5, 6). Mechanistically, C3aR- 
and CD46-mediated signals regulate IL-2R assembly and mTORC1 activation, which is required 
for the metabolic programming essential for IFN-γ induction (7). Accordingly, C3- and CD46-
deficient patients suffer from recurrent infections and have severely reduced Th1 responses in 
vitro and in vivo (5, 8). Conversely, uncontrolled intracellular C3 activation in T cells contributes 
to hyperactive Th1 responses observed in autoimmunity (3, 4, 9) that can be normalized 
pharmacologically by targeting intracellular cathepsin L function (4).  
Given the critical role of intracellular C3 processing in human Th1 biology and the 
importance of C5a generation in inflammation, we investigated whether human CD4+ T cells 
also harbour an ‘intracellular C5 activation’ system contributing to effector responses. Indeed, 
human CD4+ T lymphocytes isolated from healthy donors contained intracellular stores of C5, 
producing low levels of C5a in the resting state. TCR activation and particularly TCR + CD46 
co-stimulation increased the amounts of intracellular C5a, and this was associated with the 
secretion of C5a to the cell surface (Fig. 1A and B). C5a, as well as the C5a ‘des-Arginized’ 
form of C5a (C5adesArg) generated by carboxypeptidase processing, can bind two distinct 
GPCR receptors, C5aR1 (CD88) and C5aR2 (GPR77, C5L2) (10, 11). Binding of C5a to C5aR1 
preferentially mediates pro-inflammatory responses. The function of C5aR2 varies with cell 
type, and C5aR2 can act either as a non-signalling decoy receptor antagonizing C5aR1 or as an 
active transducer of pro- or anti-inflammatory signals (11-14). While extra- and intracellular 
localization of both C5aR1 and C5aR2 on human monocytes has been reported (14, 15), 
expression patterns in human CD4+ T have not been described in detail. Here we show 
expression of mRNA for both C5AR1 and C5AR2 in human CD4+ T cells (Fig. 1C) and protein 
by immunoblotting (fig. S1A), confocal microscopy (Fig. 1D) and flow cytometry (Fig. 1E and 
F). While mRNA amounts for C5aR1 and C5aR2 varies in T cells (Fig. 1C) (16), the protein 
levels for these receptors are comparable among donors (Fig. 1E). In resting and activated CD4+ 
T cells, C5aR1 is expressed exclusively intracellularly and in low amounts while the C5aR2 
receptor is abundantly present inside and to a lesser degree on the cell surface (Fig. 1F). We 
corroborated the specificity of reagents used for C5a receptor detection using HEK293 cells that 
had been stably transfected to express C5aR1, C5aR2 or no receptor (fig. S1B and C) and 
confirmed the ability of resting and activated human CD4+ T cells to bind C5a based on 
competitive 125I-C5a binding studies (Fig. 1G and fig. S1D). To determine whether autocrine 
engagement of the C5a receptors on T cells regulates Th1 induction, we activated human CD4+ T 
cells with immobilized antibodies to CD3, CD3 and CD28 or CD3 and CD46 in the presence or 
absence of either a specific antagonist to the C5aR1 (PMX53, 17), the C5aR1/C5aR2 receptor 
double antagonist A8Δ71-73 (dRA, 18) targeting only C5aR2 as the C5aR1 is expressed 
intracellularly, or a specific C5aR2 agonist (19). All reagents are cell impermeable. Blocking 
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C5aR2 activity significantly increased Th1 induction (Fig. 1H, left panel) and activating C5aR2 
with the agonist or with C5a or C5adesArg reduced Th1 responses (Fig. 1H, middle panel and 
fig. S1E). Blockade of the C5aR2 also led to increased Th17 (IL-17) but not Th2 (IL-4) 
responses (fig. S1F), without altering cell viability (fig. S1G). Consistent with the solely 
intracellular localization of C5aR1, the C5aR1 specific antagonist had no effect on IFN-γ 
production (Fig. 1H, right panel). However, reduction of intracellular C5aR1 by siRNA gene 
targeting led to a commensurate decrease in IFN-γ production (Fig. 1I and fig. S1H). Together, 
these data show that intracellular C5 activation contributes to induction and control of IFN-γ in 
CD4+ T cells, via combined activation of the C5aR1 and C5aR2 axes. 
To delineate the autocrine C5-driven pathways contributing to regulation of IFN-γ in 
CD4+ T cells, we performed a transcriptomic analysis using T cells from three healthy donors 
activated, or not, with anti-CD3 and anti-CD46 in the presence or absence of the C5aR1/C5aR2 
antagonist. Surprisingly, we observed enrichment of transcripts associated with inflammasome 
activation, including NLRP3 and IL1B (Fig. 2A and B and Table S1), in cells activated with anti-
CD3 and anti-CD46. Inhibition of C5aR2 further increased some of these transcripts, notably 
IL1A and IL1B (fig S2A and Table S2). IL-1α and IL-1β are prototypical pro-inflammatory 
cytokines, involved in innate immune responses and contributing to the development of several 
pathogenic autoimmune diseases including type 1 diabetes and arthritis (20-22). Both IL-1α and 
IL-1β bind to the IL-1 receptor 1 (IL-1R1). Antigen-presenting cell (APC)-derived IL-1β 
supports T cell priming and imprinting of T helper effector function (23), including enhancement 
of IFN-γ and IL-17 production from CD4+ T cells (24-26). Further, mice with deletion of the IL-
1β signal transducer MyD88 in T lymphocytes cannot generate memory T cells (27). Pro-IL-1β 
is synthesized as a 31 kDa precursor and converted to mature, 17 kDa, IL-1β via caspase-1 
cleavage (28). Caspase-1 is regulated by proteolytic activation during oligomerization with 
NLRP3 and the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), 
which is triggered in response to danger signals (29-30). NLRP3 inflammasome function has 
been described in myeloid innate immune cells, with monocytes as the main source of IL-1β (25, 
31), and in several non-immune cell types (such as microglia, endothelial and retinal pigment 
epithelial cells) (32-34); however, canonical NLRP3 inflammasome activity has not been 
demonstrated in lymphoid adaptive immune cells. We confirmed the presence of an ‘NLRP3 
signature’ in T cells by demonstrating NLRP3 and IL1B gene (fig. S2B) and protein expression, 
as well as generation of activated caspase-1 and mature IL-1β in activated human CD4+ T cells 
(Fig. 2C and D and fig. S2C to F). Consistent with our gene array data, anti-CD3 and anti-CD46 
activation led to most robust NLRP3 activation and IL-1β generation (Fig. 2D) and increased 
colocalization of NLRP3 and ASC (Fig. 2E). Notably, both resting naïve and memory CD4+ T 
cells express NLRP3 protein (fig. S2C and D). Since IL-1β supports Th1 induction (35) and is 
most strongly induced by the Th1-driver CD46, we next assessed whether inhibition of NLRP3 
activity in CD4+ T cells perturbs IFN-γ production. To this end, CD4+ T cells were activated in 
the presence of MCC950, a specific NLRP3 inhibitor (36), and Th1, Th2 and Th17 cytokine 
production measured 36 hours post activation. NLRP3 inhibition during T cell activation 
specifically attenuated IFN-γ (Fig. 2F), whereas differences in IL-4 and IL-17 production did not 
reach significance (fig. S2G) and cell viability was unaffected as well (fig. S2H). The effects of 
the NLRP3 inhibitor could be fully reversed by the addition of rhIL-1β to cultures (Fig. 2G). 
Similarly, reduction of active caspase-1 activity by the specific inhibitor Z-YCAD-FMK 
repressed IL-1β and IFN-γ secretion (fig. S2I and Fig. 2H) and rhIL-1β provision normalized 
Th1 induction in these cultures. The role for IL-1β as critical autocrine ‘Th1 supporter’ is 
5 
 
reinforced by our observation that no IL-18 (which also depends on NLRP3 activation and can 
support Th1 responses (37) was measurable in our cultures and that addition of IL-18 binding 
protein had no effect on cytokine production (fig. S2J).  
To further explore this pathway, we measured the effects of NLRP3 hyperactivity in 
CD4+ T cells isolated from the blood of patients with distinct gain-of-function mutations in 
NLRP3 (patient characteristics are summarized in Table S3). This class of NLRP3 mutations is 
associated with a group of heritable monogenic syndromes known as cryopyrin-associated 
periodic syndromes (CAPS), characterized by excessive production of IL-1β from antigen 
presenting cells with recurrent fevers, skin rashes, joint and ocular inflammation and amyloidosis 
(38). Therapeutic suppression of the inflammatory responses can be achieved by IL-1R blockade 
with the IL-1 receptor antagonist anakinra, or canakinumab, a monoclonal antibody targeting IL-
1R1 (38-39). Despite their medication regimen and the fact that cytokine production by immune 
cells from CAPS patients can vary with their respective ‘flare status’ (40), T cells from CAPS 
patients had significantly increased IL-1β secretion compared to sex- and age-matched healthy 
donors (fig. S2K), indicating that increased NLRP3 activity in CD4+ T cells indeed induces 
heightened IL-1β secretion. We next performed a more in-depth analysis of T cell in vitro 
responses from another cohort of seven CAPS patients (Table S4). All patients had a naïve 
versus memory T cell distribution comparable to those of healthy donors (fig. S2L) and T cells 
from five patients showed also significantly increased IL-1β secretion upon activation (Fig. 2I). 
Furthermore, CD4+ T cells from these patients produced substantially more IFN-γ when 
compared to T cells from sex- and age-matched healthy donors and a statistically significant 
correlation between increased IL-1β and IFN-γ secretion (Fig. 2J and K), but displayed 
significantly reduced IL-17 responses (Fig. 2L). Although caspase-1 activity was not 
significantly increased in the patients’ T cells at the time point assessed (36 hours), the patients 
with highest IL-1β secretion also had the highest active caspase-1 levels (fig. S2M), and NLRP3 
inhibition with MCC950 led to reduction of both IL-1β and IFN-γ secretion (Fig. 2M). Together, 
these data demonstrate that human CD4+ T cells produce IL-1β in an NLRP3-dependent manner, 
that autocrine IL-1β generation supports IFN-γ secretion and, importantly, that dysregulation of 
this pathway occurs in human auto-inflammatory disease. 
We next asked whether C5aR signalling could directly regulate NLRP3 activity in human 
CD4+ T cells. C5aR2 blockade in CD3+CD46-activated T cells further increased IL1B but not 
NLRP3 mRNA (fig. S3A and B). Enhanced IFN-γ in this context could be reversed by inhibition 
of NLRP3 with MCC950 (Fig. 3A) without affecting IL-4 or IL-17 production (fig. S3C). 
Pharmacological targeting of C5aR2 via either the dRA or a C5aR2 agonist revealed that C5aR2 
negatively regulates active caspase-1 and mature IL-1β expression in T cells (Fig. 3B to D) but 
does not affect NLRP3 protein levels per se (fig. S3D). Silencing of C5AR1 expression had also 
no effect on NLRP3 protein levels (fig. S3E) but reduced active caspase-1 (Fig. 3E) and IL-1β 
expression (Fig. 3F) and, importantly, the reduction of IFN-γ secretion after C5AR1 gene 
silencing was ‘rescued’ by addition of rhIL-1β (Fig. 3G). Together these data suggest that CD46-
mediated signals increase NLRP3 mRNA expression in T cells while C5aR1 supports subsequent 
NLRP3 assembly and C5aR2 is a negative regulator of this process.  
Reactive oxygen species (ROS) are ‘classical’ upstream stimulators of NLRP3 activation 
(41) and are strongly induced by C5aR1 in monocytes and neutrophils (42). Furthermore, 
generation of ROS within CD4+ T cells is required for T cell activation and induction of IL-2, a 
key cytokine for Th1 biology (43). We therefore assessed whether autocrine C5 activity in T 
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cells regulates NLRP3 via ROS generation. We observed potent generation of ROS in anti-CD3 
and anti-CD46-induced Th1 cells (Fig 3H) and poor Th1 induction in the presence of a ROS 
inhibitor (Fig. 3I). Inhibition of C5aR2 significantly increased ROS in T cells in contrast to 
silencing of C5aR1, which reduced ROS species (Fig. 3J). Enhanced IFN-γ production with 
C5aR2 blockade could be entirely reversed by the presence of an ROS inhibitor (Fig. 3I and fig. 
S3F), suggesting that NLRP3 activation in human T cells involves intracellular C5-driven ROS 
production.   
To address the in vivo significance of NLRP3-driven autocrine IL-1β production by CD4+ 
T cells, we analysed CD4+ T cell responses of Nlrp3–/–, Il1a–/–/Il1b–/– and Il1r1–/– mice. Similar to 
human CD4+ lymphocytes, CD4+ cells from wild type (WT) mice expressed NLRP3 and IL-1β 
while neither NLRP3 nor IL-1β mRNA (Fig. 4A) and protein (fig. S4A) were detectable in T 
cells from respective gene deficient animals. We observed no difference in the proportion of 
naïve versus memory T cells or in T cell survival between WT and knockout strains (fig. S4B 
and C). However, upon in vitro CD3+CD28 activation, CD4+ T cells from Nlrp3–/–, Il1a–/–/Il1b–/–
, and Il1r1–/– mice had a reduction of ~75 % in IFN-γ production when compared to T cells from 
WT animals (Fig. 4B); in contrast, IL-10, IL-4 and IL-17 production were unaffected in all three 
mouse mutant lines (fig. S4D). While activation of WT mouse T cells in the presence of the 
NLRP3 inhibitor MCC950 had no effect on cell viability (fig. S4E), only IFN-γ production was 
reduced significantly (Fig. 4C and fig. S4F), indicating that diminished IFN-γ secretion in the 
knockout T cells was not due to a developmental defect and that NLRP3 activity is required for 
normal IFN-γ induction. Moreover, both naïve and memory mouse CD4+ T cells displayed a 
requirement for NLRP3-driven IL-1β activity for optimal IFN-γ secretion (fig. S4G and H). 
Using a lymphocytic choriomeningitis virus (LCMV) model (Fig. 4D) we demonstrated an in 
vivo role for NLRP3-driven IL-1β generation in Th1 responses during infection. Irradiated mice 
were reconstituted with equal parts bone marrow cells from WT mice together with either Nlrp3–
/–, Il1a–/–/Il1b–/– or Il1r1–/– bone marrow cells, prior to infection with LCMV. Analysis of splenic 
CD4+ T cells 12 days post infection revealed that all animals generated comparable numbers of 
GP66-77+Ki67+LCMV tetramer+ cells at 12 days post infection (Fig. 4E and F), indicating that 
Nlrp3–/–, Il1a–/–/Il1b–/–, and Il1r1–/– CD4+ T cells survived normally. However, T cells deficient 
in any of these components displayed substantially reduced IFN-γ+ virus-specific cells in vivo 
(with an average decrease of ~50%) (Fig. 4G and H). We further demonstrated the in vivo 
importance of autocrine NLPR3 activity in CD4+ T cells, by assessing its influence on disease 
outcome in a CD4+ T cell transfer model of colitis, where IL-1β and both Th1 and Th17 
responses in the intestine have been shown to be involved (44, 45). Animals that had received 
Nlrp3–/– CD4+ T cells developed more severe disease with significantly increased weight loss, 
reduction in colon length and higher disease scores when compared to mice injected with WT 
CD4+ T cells (Fig. 4I to K). Similar to our observation in the LCMV model, colonic Nlrp3–/– T 
cells displayed a substantial reduction in IFN-γ production (average decrease ~45%) but also a 
concurrent increase in Th17 responses (Fig. 4L and M). These observations were confirmed 
using a CD4+ T cell-driven model of graft versus host disease (GvHD) where mice receiving 
Nlrp3–/– T cells displayed more severe illness with reduced Th1 and increased Th17 induction 
(fig. S5A to D). Together these data demonstrate that the NLRP3 inflammasome mediates 
functionally important CD4+ T cell intrinsic effects that control normal IFN-γ production and the 
Th1/Th17 balance during (at minimum) intestinal inflammation. These latter findings align with 
the observation that T cells from CAPS patients have indeed increased Th1 but decreased Th17 
responses (fig. 2J and L).  
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Although CD4+ T cells from C5ar2–/– mice have increased in vitro IFN-γ production 
which was reduced to normal levels by MCC950 treatment (fig. S5E) and C5ar1–/– mice have 
impaired in vitro and in vivo Th1 responses (46), there are clear species-specific differences in 
the relative contributions of complement receptor activities in IL-1β and/or IFN-γ induction. For 
example, the role and expression of anaphylatoxin receptors on mouse T cells remains a matter 
of controversy and mice lack expression of CD46 (or a full functional homologue) on somatic 
tissue (47). Further, as IL-1β also boosts the production of other cytokines including IL-4 and 
IL-17 (35), the engagement of the complement/NLRP3 inflammasome axis in T cells and its 
functional outcome could be context-dependent (infection, autoimmunity etc.). For example, 
Bruchard et al. recently observed a non-canonical function for NLRP3 in mouse CD4+ T cells 
(they did not study human CD4+ T cells), independent of inflammasome formation and IL-1β 
secretion, during Th2 induction and tumor growth (48). 
 
In summary, we establish here that that NLRP3 inflammasome function is not confined to 
innate immune cells but is operative in adaptive CD4+ T cells and, via autocrine IL-1β activity, 
required for the optimal production of the key host defense factor, IFN-γ. Further, and 
unexpectedly, NLRP3 assembly in human T cells requires TCR-induced intracellular C5 
activation and stimulation of intracellular C5aR1. Secretion of intracellularly generated 
C5a/C5ades-Arg engages the surface-expressed ‘alternative’ C5aR2 which negatively controls 
NLRP3 activation (either through inhibition of C5aR1 or a yet undefined mechanism). We 
envisage that, whereas APC-derived NLRP3-activated IL-1β supports initial Th1 priming, 
maintenance of the Th1 phenotype during differentiation and migration into the periphery may 
rely on autocrine NLRP3 activity. IL-1β production by T cells, relative to myeloid cells, is 
comparatively low and tightly regulated by an autocrine C5aR1 vs. C5aR2 activation balance 
(fig. S6A), likely because rapid control of local IL-1β is critical to normal termination of Th1 
responses: human Th1 cells co-induce IL-10 secretion in an CD46-dependent fashion during 
their contraction phase and failure of this ‘IL-10 switch’ underlies hyperactive Th1 responses 
observed in rheumatoid arthritis and multiple sclerosis (3, 9). IL-1β is a strong suppressor of IL-
10 production (23) and, accordingly, blockade of C5aR2 increased the IFN-γ:IL-10 ratio (fig. 
S6B). Further, IL-1β addition to cultures increased IFN-γ but blocked IL-10 secretion (fig. S6C) 
and T cells from CAPS patients have significantly reduced IFN-γ to IL-10 switching (fig. S6D).  
Thus, the regulated crosstalk between intracellularly activated complement components 
(‘complosome’) and the NLRP3 inflammasome emerges as fundamental to human Th1 induction 
and regulation (and possibly regulating Th1/Th17 balance in inflammation). That established 
innate immune pathways previously not thought to be operative in adaptive immune cells are not 
only present but also are key in directing immunological responses is of substantial significance 
to our understanding of immunobiology and immune system evolution. Further, the possibility 
that this normal functional crosstalk may also be target of viral immune evasion strategies (49), 
suggests that the complement-NLRP3 axis in T cells could represent a novel therapeutic target 
for the modulation of IFN-γ responses in autoimmunity and infection. In this regard, it will be 
valuable to explore whether optimal production of IFN-γ by CD8+ T cells (50), natural killer T 
(NKT) cells, and /or innate lymphoid type 1 (ILC1) cells also relies on autocrine complement-
NLRP3 inflammasome activity.  
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Figure Legends  
 
Fig. 1. Autocrine activation of C5a receptors regulates IFN-γ production by human CD4+ T 
cells. (A and B) Intracellular C5 and C5a generation in CD4+ T lymphocytes, left non-activated 
or activated (36 hours) with α-CD3, α-CD3 + α-CD28 or α-CD3 + α-CD46 by flow cytometry 
(A) and confocal microscopy (B) (data representative of n=3). (C) RT-PCR analysis for C5AR1 
and C5AR2 mRNA in resting human CD4+ cells and monocytes (n=4, donors D1-D4, 
endogenous control ACTB). (D) Intracellular immunofluorescence on resting T cells and 
monocytes with antibodies to C5aR1 (green) and C5aR2 (red) (data representative of n=3). (E) 
C5aR1 and C5aR2 protein amounts in T cells with expression normalized to respective isotype 
control staining for each donor (ΔMFI ± SEM, n=6). (F) Flow cytometry for C5aR1 and C5aR2 
on resting T cells and monocytes, with representative histogram plots shown (n=6). (G) Binding 
of radioactively-labelled 125I-C5a in absence or presence of non-labelled ‘cold’ C5a as 
competitor to resting or α-CD3 + α-CD46 activated (4 hours) T cells (n=6). (H) IFN-γ secretion 
in non-activated (NA) and activated (36 hours) CD4+ T cells in the absence or presence of either 
a C5aR1/C5aR2 double receptor antagonist (n=9), a C5aR2 agonist (n=8) or a C5aR1 antagonist 
(n=7). (I) IFN-γ production by T cells transfected with C5aR1-specific siRNA or a scrambled 
control siRNA (Ctrl. siRNA) 36 hours post activation (n=7). Error bar graphs represent mean ± 
SEM. *p <0.05, **p <0.01, ****p <0.0005. 
 
Fig. 2 NLRP3 inflammasome activation occurs in CD4+ T cells and enhances IFN-γ 
production. (A) Gene Set Enrichment Analysis (GSEA) for inflammasome-related genes in 
CD4+ T cells after α-CD3 + α-CD46 activation (2 hours) compared to resting cells (donors D1-
D3). (B) Heatmap depicting leading edge analysis (the core enriched genes) of the data in (A). 
(C) NLRP3 immunoblot (upper panel) and immunofluorescence (lower panel) on CD4+ 
lymphocytes and monocytes. (D) NLRP3, activated caspase-1 and total IL-1β protein expression 
in activated CD4+ cells (data representative of n=3). (E) Representative immunofluorescence co-
staining for NLRP3 (green) and ASC (red) on resting and α-CD3 + α-CD46 activated T cells (r = 
Pearson’s correlation coefficient between NLRP3 and ASC fluorescence, n=3). (F and G) IFN-γ 
production by resting (NA) and activated CD4+ T cells with or without MCC950 addition (n=7) 
(F) and with or without rhIL-1β supplementation (n=3) (G). (H) IFN-γ production in presence of 
the specific caspase-1 inhibitor Z-YVAD-FMK with or without rhIL-1β addition. (I) IL-1β 
secretion from resting and α-CD3 + α-CD46 activated CD4+ cells from seven patients with 
CAPS (P8-P14, individual values) and five healthy sex- and age-matched donors (HD5-HD9, 
combined values). (J) IFN-γ secretion by resting and activated CD4+ cells from seven patients 
with CAPS (P8-P14) and seven sex- and age-matched healthy donors (HD5-11). (K) Correlation 
between IL-1β and IFN-γ production in T cells from patients P8-P14 upon α-CD3 + α-CD46 
activation (Spearman correlation analysis). (L) IL-17 production by resting and activated T cells 
from CAPS patients P8-P14 and healthy donors H5-H11. (M) IFN-γ and IL-1β secretion by 
CD4+ T cells from P8, P11 and P14 post α-CD3+α-CD46 activation with or without MCC950 
treatment (% normalized to non-treated). Analyses on (D - M) were performed at 36 hours post-
activation. Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01, ***p <0.001, ****p 
<0.0005. 
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Fig. 3 C5a receptors regulate NLRP3 activation to modulate IFN-γ responses. (A) IFN-γ 
production in CD4+ T cells either left non-activated (NA) or activated as depicted with or 
without addition of the C5aR1/C5aR2 antagonist and/or MCC950 (n=3). (B and C) 
Measurement of active caspase-1-positive CD4+ T cells activated with α-CD3 + α-CD46 with or 
without MCC950, the C5aR1/C5aR2 antagonist or the C5aR2 agonist (n=3) (B) and statistical 
analyses of data obtained (C). (D) Corresponding IL-1β secretion in activated CD4+ cells treated 
as in (B) (n=5). (E and F) Active caspase-1 levels (E, n=4) and IL-1β secretion (F, n=7) in T 
cells after transfection with either C5aR1-specific siRNA or scrambled control (Ctrl.) siRNA. 
(G) IFN-γ production in activated CD4+ T cells after transfection with C5aR1-specific siRNA or 
a scrambled control siRNA (Ctrl. siRNA) with or without addition of rhIL-1β (n=3). (H) ROS 
production in CD4+ T cells activated under the depicted conditions (data representative of n=3). 
(I) IFN-γ production from CD4+ T cells left non-activated or activated as indicated with and 
without a specific ROS inhibitor and/or the C5aR1/C5aR2 antagonist (n=3). (J) ROS production 
in α-CD3 + α-CD46 activated CD4+ cells with or without the C5aR1/C5aR2 double antagonist 
(left panel) or after transfection with C5aR1-specific siRNA (right panel) (data representative of 
n=3). Analyses were performed at 36 hours post-activation. Error bar graphs represent mean ± 
SEM. *p <0.05, **p <0.01, ***p <0.001. 
 
Fig. 4 NLRP3 function in CD4+ T cells is required for optimal IFN-γ responses in vivo. (A) 
RT-PCR analysis on CD4+ T cells isolated from wild type (WT), Nlrp3–, combined Il1a–/– and 
Il1b–/– (Il1a/b–/–) and Il1r1–/– mice for corresponding gene mRNA expression. (B) Cytokine 
secretion from CD4+ T cells isolated from WT and knock out mice at 96 hours post α-CD3 + α-
CD28 activation (n=3). (C) Cytokine production from CD4+ T cells from WT and Nlrp3–/–mice 
post α-CD3 + α-CD28 activation (96 hours) with or without addition of MCC950 (n=4). (D) 
Schematic of the acute Lymphocytic Choriomeningitis Virus (LCMV) infection model employed 
in this study. (E and F) Percentage of LCMV tetramer-positive CD4+ T cells isolated from the 
spleens of the three bone-marrow chimeric mice groups used 12 days post infection (E) and 
percentages of Ki67+GP66-77+/tetramer-positive cells (F). (G and H) Representative 
intracellular IFN-γ staining in splenic CD4+ T cells of one mouse from each group after LCMV 
peptide re-stimulation (5 hours) (G, n=6) with corresponding statistical analyses (H, n=6). (I-M) 
Naïve splenic CD25-CD45RBhi CD4+ T cells from WT or Nlpr3–/– mice were transferred into 
C57BL/10 RAG2–/– mice. (I) Weight change over the course of colitis induction. (J) Colon 
length at the study endpoint. (K) Inflammation score of the colons according to blinded histological 
analysis with assessment of inflammation (left panel), epithelial damage (middle panel) and muscular 
immune cell infiltration (right panel). (L-M) Intracellular IFN-γ and IL-17A staining of colonic 
CD4+ T cells at the study endpoint after overnight α-CD3 + α-CD28 stimulation and brefeldin A and 
monensin addition for 5 hours (Gated on live CD4+ Thy1.2+ T cells). Representative flow cytometric 
plots (L) with corresponding statistical analysis shown from 2 combined independent experiments 
(M, n=13 WT, 15 KO). Error bar graphs represent mean ± SEM *p <0.05, **p <0.01. 
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Materials and Methods 
 
Healthy donors and patients 
Blood samples were obtained with ethical and institutional approvals (Wandsworth Research Ethics Committee, 
REC number 09/H0803/154). T cells were purified blood samples from healthy volunteers after informed consent. 
Fourteen adult patients with cryopyrin-associated periodic syndrome (CAPS) were recruited at the National 
Amyloidosis Centre, University College London (Ethical approval REC reference number 06/Q0501/42) with key 
information on the patients summarized in Table S3. In all experiments that involved T cells from CAPS patients, T 
cells from age- and sex-matched healthy volunteers were used as controls.  
 
Mice used in the study 
All mice used in this study are on a C57BL/6 background (with the exception of the GvHD experiment, were Balb/c 
mice were used). Wild type and Il1r1–/–mice were purchased from Jackson Laboratories and subsequently 
backrossed to B6 for 10 generations at the NIH (Bar Harbor, ME). The C5ar2–/– (human gene symbol GPR77, and 
gpr77–/– mice) mice were previously described (12), Nlrp3–/– animals were provided by Vishwa Dixit of Genentech 
and mice deficient in Il1a and Il1b (Il1a/Il1b–/– animals) were kindly provided by Y. Iwakura (Tokyo University) 
(51). The C57BL/10 RAG2–/– mice were obtained from Taconic. All animals were maintained in AALAC-
accredited BSL2 or BSL3 facilities at the NIH or FDA and experiments performed in compliance with an animal 
study proposal approved by the NIAID or FDA Animal Care and Use Committee.  
 
Antibodies, proteins, agonists and antagonists  
Cell-stimulating mAbs to human CD4+ T cells were bought from BD Biosciences, San Diego, CA (anti-hCD28, 
CD28.2), purified from a specific hybridoma (anti-hCD3; OKT-3) or generated in-house (anti-CD46; TRA-2-10) 
(52). Mouse T cells were activated with anti-CD3 (145-2C11) and anti-CD28 (37.51) from Bio X Cell (West 
Lebanon, NH). The anti-human/mouse NLRP3 (ab4207), anti-human C5 (ab66850) and C5a (ab11878), anti-
human/mouse IL1-β (ab9722) and anti-human β-actin (ab8226) antibodies were purchased from Abcam 
(Cambridge, UK). The anti-human C5a antibody was also biotinylated in house using the APEX™ Biotin-XX 
Antibody Labeling Kit (Life Technologies Ltd, Paisley, UK). Alternative antibodies to human/mouse 
NLRP3/NALP3 (Clone 768319) and human/mouse IL-1β (3A6, used for Western blotting and FACS experiments) 
were purchased from R&D Systems (Minneapolis, MN) and Cell Signalling Technology (Beverly, MA), 
respectively. Additional antibodies used include anti-human NLRP3/NALP3 (AG-20B-0014-C100) and ASC 
(AL177) from Adipogen (Liestal, Switerland), anti-hC5aR1 (sc-53795) and anti-hNLRP3 (sc-34408) from Santa 
Cruz (Dallas, TX), anti-hC5aR2 (ID9-M12) and anti-hCD45RA from Biolegend, anti-hIL-1β (12-7018-81) and anti-
hCD4 from eBioscience (San Diego, CA), anti-hC5aR1 (MCA2059; AbD Serotec, Oxford, UK), anti-hC5aR2 
(PA1-41397; Thermo Scientific (Leicestershire, UK)), and anti-hcaspase-1 (3019-100; Biovision (Milpitas, CA)). 
The antibodies recognizing anti-human-CD25, CD45RA (555488), and CD45RO (559865) were purchased from 
BD Biosciences. The following mouse antibodies were purchased from Biolegend: Mouse Trustain (Fc-Block), anti-
CD44 FITC, PE-cy7 or BV421, anti-mouse IFN-γ PE, anti-mouse CD4 (APC-cy7, BV 421 or BV605), anti-mouse 
CD45.1 FITC and CD45.2 PerCP, anti-mouse CD45RB FITC, anti-mouse CD25 APC. Anti-mouse/human Ki67 
was purchased from BD Biosciences. The secondary antibodies anti-rabbit IgG H+L chain Alexa Fluor 594 
(ab150076), anti-goat IgG H+L chain PE (ab7004) and anti-goat IgG H+L chain Alexa Fluor 488 (ab150129) were 
from Abcam, while anti-mouse IgG Alexa Fluor 488 (A11001), anti-rabbit IgG H+L chain Alexa Fluor 594 
(A11037) and anti-rat IgG H+L chain Alexa Fluor 488 (A11006) were obtained from Molecular Probes/Life 
Sciences (Paisley, UK). APC streptavidin was purchased from Biolegend.  
Recombinant active human IL-1β was bought from Abcam and used at 20 ng/ml in cultures, recombinant human 
IL18BPa (Sino Biologicals Inc.) was used at 50 µM, human IL-2 was provided by C. Pham (Washington University 
in Saint Louis, MO) and lipopolysaccharide (LPS) was purchased from Sigma Aldrich (Saint Louis, MO). 
Recombinant C5 and C5adesArg were purchased from CompTech (Tyler, TX). The specific C5aR1 antagonist 
(PMX53) (17) was provided by T. Woodruff (University of Queensland, AU) and used at 10 µM, the C5aR1/C5aR2 
double antagonist a gift from J. Köhl (University of Lübeck, Germany) (18) and used at 7 µM, and the specific 
C5aR2 agonist (RHYPYWR) was generated by T. Woodruff and P. Monk (Sheffield University, UK) (19) and used 
at 100 µM. The specific NLRP3 inhibitor MCC950 (36) was used at 10 µM, the specific caspase-1 inhibitor Z-
YVAD-FMK (Abcam) was used at 20 µM and  the reactive oxygen species (ROS) inhibitor Diphenyleneiodonium 
(DPI) (Sigma Aldrich) was added at 750 nM. In all experiments, cells were incubated in media for 15 minutes 
including the compound of choice (incubation with the corresponding vehicle buffer was used as control) before 
activation and culture.  
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Cell isolation and activation 
Human cells: CD4+ T cells and monocytes were isolated from blood as previously published using the MACS 
Human CD4+ Positive T cell Isolation Kit or the MACS Human CD14+ Cell Positive Isolation Kit (both Miltenyi, 
Biotech Ltd, Bisley, UK), respectively (7). Purity of bead-isolated T lymphocyte fractions was typically > 98% and 
for monocytes > 95%. For (naïve and memory) CD4+ T cell sorting, cells were stained with appropriate antibodies 
(naïve cells: CD4+, CD45RA+, CD45RO−, CD25− and memory cells: CD4+, CD45RA-, CD45RO+, CD25−) and 
sorted with a BD FACSAria™ II Cell Sorter (KCL Flow Core facility). CD4+ T cells were activated in 48-well 
culture plates (2.5 – 3.0 x 105 cells/well) coated with mAbs to CD3, CD28 or CD46 (2.0 µg/ml PBS each) and 
addition of 25 U/ml rhIL-2, thus, under non-skewing conditions. Monocytes were activated in 24-well plates (2.5 – 
5.0 x 105 cells/well) by addition of LPS (50 ng/ml). Cell viability was monitored by using either propidium iodide 
(BD Biosciences) or the LIVE/DEAD Cell Viability Assay (Life Technologies).  
Mouse cells: Single cell suspensions of spleen cells were generated and red blood cells lysed using ACK lysis buffer 
(Life Technologies). CD4+ T cells were isolated by negative selection using the Stem Cell Technologies EasySepTM 
Mouse CD4+ T Cell Isolation Kit (Tukwila, WA). To obtain pure CD4+ T cell populations, CD4+ cells were sorted 
using a FACS Aria (BD Biosciences) based on CD4+CD45.2+ staining and to separate naïve versus memory CD4+ T 
lymphocytes. T cells were sort-separated based on CD4+ CD44+ (memory) and CD4+ CD44- (naïve) stainings. For in 
vitro T cell activation, 48- or 96-well plates were coated with 2 ug/ml anti-CD3 overnight at 4°C and CD4+ T cells 
(0.5 – 1.0 x 106 per well of 48-well plates or 0.2 x 106 per well of 96-well plates) were added to the appropriate 
wells. One ug/ml of anti-CD28 was added to the media to provide co-stimulation.  
 
Lymphocytic choriomeningitis virus (LCMV) infection in mice 
Preparation of mixed bone marrow (BM) chimeric mice: B6.SJL (CD45.1,1) mice were lethally irradiated (950 rad) 
and reconstituted with a total of 107 donor BM cells from C57BL/6 CD45.1,2 wild-type (WT) mice mixed at equal 
parts with BM cells from CD45.2,2 mice deficient (KO) in either Nlrp3-/-, Il1r1-/-, or Il1a/Ilb-/-. Mice were allowed 
to reconstitute for 10 weeks before infection with LCMV.  
LCMV infection and assessment of antigen-specific CD4+ T cell response: Ten weeks post-reconstitution, the mice 
were infected with 105 pfu of LCMV-Armstrong intraperitoneally. On day 12 post-infection, the mice were 
euthanized and the spleens removed for processing. For ex vivo cytokine staining of mouse cells after LCMV 
infection, cells were incubated with 1 ug/ml of LCMV GP61-80 peptide in the presence of monensin and brefeldin 
for 5 hours at 37 oC. Staining for LCMV-specific CD4+ T cells was performed using an APC-labeled 1Ab LCMV 
GP66-77 tetramer (NIH tetramer core facility) as described previously (53). Data were acquired with a FACS 
Calibur, Fortessa LSRIII or FACS Aria cytometer (BD Biosciences) and analyzed with FlowJo 10.0.8 software 
(Ashland, OR). 
 
Induction of colitis and colon cell isolation 
Splenic CD4+ T cells were isolated from C57BL/6 or Nlpr3–/– mice using a negative selection CD4 T cell 
enrichment kit (Stemcell tech), were stained with anti-CD45RB FITC, anti-CD25APC and anti-CD4 BV421, and 
sorted on a FACS Aria (BD biosciences) for CD4+ CD25-CD45RBhi (brightest 35%) cells. 2 x 105 of WT or Nlpr3–/–
cells were injected i.p. into age and sex matched C57BL/10 RAG2–/– mice. The mice were sacrificed when 
symptoms of clinical disease (5-10% weight loss of original bodyweight and/or diarrhea) were observed in at least 
one group, approximately 6-11 weeks after adoptive transfer. Colon lamina propria cells were isolated as described 
previously (54), with the additional step of further purifying the cells over a 44% and 67% Percoll gradient to enrich 
for the mononuclear cells. 
 
Scoring of intestinal inflammation 
Samples of the proximal, mid and distal colon were excised after feces were flushed from the colons, placed into 
3.7% formaldehyde solution, and then paraffin embedded. Cross-sectional sections were cut and stained with 
haematoxylin and eosin (H&E). Colon pathology scores were based on severity of mononuclear cell inflammation, 
intestinal wall thickening, including infiltration to the muscularis, and epithelial damage, including edema, 
degeneration, and necrosis on a graded scale where 0 = normal, 0.5 = very mild, 1 = mild, 2 = moderate, 3 = severe. 
Samples were scored blinded by a pathologist from the NIH Pathology Score. 
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Induction of graft versus host disease (GvHD) 
Balb/c mice were lethally irradiated with 900cGy (two doses of 450cGy 3 hours apart) on day -1. C57BL/6 WT 
bone marrow was depleted of T cells using the CD90.2 Positive Selection Kit (Stemcell tech) and 5 x 106 cells were 
transferred on the following day (day 0) alone (control), or in addition to 1 x 106 WT B6 or Nlpr3–/– naïve CD4+ T 
cells isolated with the Negative Selection Naïve CD4 T Cell Kit (Stemcell tech).  Mice were sacrificed upon clinical 
symptoms of disease (diarrhea and weight loss) on day 12 post cell transfer. 
 
Detection of active caspase-1 and reactive oxygen species (ROS) 
Generation of cleaved and active caspase-1 in cells was monitored by Western blotting for appropriate active 
fragment generation and by using the Green FLICA Caspase-1 Assay Kit (ImmunoChemistry Technologies, 
Bloomington, MN) according to the manufacturer’s protocol with subsequent FACS analysis. ROS staining was 
performed by incubating cells to be assayed in 17 µg/ml dihydrorhodamine (DHR) 123 diluted in Hank’s balanced 
salt solution with 10 mM HEPES (all from Sigma Aldrich) for 15 minutes at 37 °C. Data were acquired on a FACS 
Calibur or Fortessa LSRIII cytometer (BD Biosciences) and analyzed with FlowJo software. 
 
Confocal microscopy 
Cells were fixed and permeabilized using the Cytofix/Cytoperm Kit (BD Biosciences) and stained with the indicated 
primary antibodies overnight and with secondary antibodies 30 min at 4 °C. Cells were mounted using 
VECTASHIELD media with DAPI (Vector Laboratories Ltd., Burlingame, CA) and images were acquired with a 
Nikon A1R confocal microscope (Nikon Imaging Centre, King’s College London, London, UK) and analyzed using 
NIS Elements (Nikon, Surrey, UK) and ImageJ software (National Institute of Health, MD).  
 
Binding studies with recombinant human 125I-C5a 
CD4+ T cells from healthy donors were left non-activated or activated for 4 hours with immobilized antibodies to 
CD3 and CD46 and then incubated for 2 hours at 4 °C (1 x 107 cells/ml) with 10 µl of 0.1 nM 125I-rhC5a (Perkin 
Elmer, Boston, MA, USA) and either 400 nM non-labelled rhC5a in HAG-CM buffer (1 mM CaCl2, 1 mM MgCl2, 
0.25% bovine serum albumin, 0.5 mM glucose, pH 7.4) or buffer without rhC5a addition. Cells were vacuum-
transferred onto 96-well MultiScreen-HV filter plates (MAHVN4510; Millipore/Merck, Darmstadt, Germany), non-
bound 125I-rhC5a removed by washing and cell-bound 125I-rhC5a detected on the filter membranes by 125I using a 
Packard Cobra II Gamma Counter (Perkin Elmer, Schwadorf, Austria). For binding controls, human embryonic 
kidney (HEK 293) cells (ATCC CRL 1573) were stably transfected with the pQCXIN vector expressing hC5aR1 or 
hC5aR2 (leading to expression of >1 Mio. of the respective C5aR/cell) or with the ‘empty’ vector as control (55) 
(these cell lines also served as specificity controls for the anti-C5a receptor antibodies used in this study). In order to 
get comparable low cpm-values as observed with purified T cells, only 5 x 104 cells/ml of C5aR1- or C5aR2-
expressing HEK cells were applied. They were diluted in buffer containing ‘no-C5aR-expressing control’ cells. The 
constant higher number of cells (5 x 105 HEK cells/ml in the 30µl volume later used in the binding assay) permitted 
repetitive washing without cell-loss and ensured identical non-specific binding in all samples containing the same 
cell type. C5aR1- , C5aR2-expressing or control HEK 293 cells were incubated for 1 hour with or without 100 nM 
of non-labelled rhC5a, washed thoroughly and then incubated for additional 2 hours with 10 µl of 0.1 nM 125I-rhC5a. 
After removal of non-bound rhC5a, binding of 125I-C5a to the respective HEK 293 cell lines was determined by 
measuring gamma radioactivity. To exclude C5a-induced C5aR-internalization during all binding studies all steps in 
the binding experiments were performed at 4°C and HEK 293 cells were additionally pre-incubated 15 minutes at 
37°C with 0.1% NaAcid and 21 µg/ml Cytochalasin B, and then cooled on ice for 5 minutes before their incubation 
with rhC5a.  
 
Cytokine measurements  
Cytokine production by cells in culture was quantified from cell supernatants using either the human or mouse 
Th1/Th2/Th17 Cytometric Bead Array (BD Bioscience) or via intracellular cytokine staining after treated for 4 
hours with 50 ng/ml PMA, 1 µg/ml ionomycin (both Sigma Aldrich) and 1 x Golgi Plug (BD Biosciences). Secreted 
human IL-1β and IL-18 were measured using the Human IL-1β/IL-1F2 DuoSet Kit or the Human IL-18/IL-1F4 
Elisa kit (R&D Systems and eBiosciences, respectively) in combination with SIGMAFASTTM OPD tablets (Sigma 
Aldrich) as substrate for detection. 
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RNA extraction, RT-PCR and quantitative RT-PCR 
RNA was extracted utilizing the RNeasy Mini Kit including DNAse digestion and DNA cleanup (Qiagen, Limburg, 
The Netherlands) and reverse transcription performed with the One Step RT-PCR (Qiagen). For quantitative PCR, 
RNA was reverse-transcribed with 2.5 µM random hexamers, 1 mM dNTPs, 40 U RiboLock RNAse inhibitor and 
400 U RevertAid H Minus Reverse Transcriptase (Thermo Scientific). Quantitative-PCR was performed using KI-Q 
Hot Start Sybr Green Mix (Sigma Aldrich), with 150 pmol forward and reverse primers and data acquired on the 
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hertfordshire, UK). Primer sequences are listed in 
Table S5.  
 
RNA silencing  
SiRNA targeting human C5AR1 mRNA and control scrambled siRNA were purchased from Origene (Rockville, 
MD) and delivered at a final concentration of 15 nM (mixture of 3 different C5aR1 siRNA used at 5nM each or 
scramble control at 15nM) into primary human CD4+ T cells by transfection with Lipofectamine RNAiMAX (Life 
Technologies, Paisley, UK) following the manufacturer’s instructions. C5AR1 mRNA level reduction was 
consistently about 30 %.  
 
Microarray data generation and analysis 
Transcriptome profiling was performed by the KCL Genomic Centre (London, UK) utilizing human exon 1.0 ST 
arrays (Affymetrix, High Wycombe, UK) on CD4+ T cells isolated from three different healthy donors that were left 
either non-activated or were activated with antibodies to CD3 and CD46 for 2 hours in the absence or presence of 
the C5aR1/C5aR2 antagonist. Expression data were analyzed using Partek Genomics Suite (Partek Inc., St Louis, 
USA) version 6.6 and Gene Set Enrichment Analysis, GSEA (56) (Broad Institute of MIT and Harvard, USA) with a 
normalized enrichment score of 1.8 to derive normalized enrichment score (NES), nominal p-value and FDR q-
value. Microarray datasets were used in conjunction with the Qiagen-generated inflammasome gene set (Qiagen 
Sciences Inc, USA) (84 members). Heatmaps for the leading edge subset were drawn with Partek genomics suite. 
Table S1 shows the normalized read values from microarrays for Fig. 2A and B. The list of annotated genes 
differentially regulated by the C5aR1/C5aR2 double antagonist (fig. S2) is given in Table S2. 
 
Statistical analysis  
Analyses were performed with GraphPad Prism (La Jolla, CA). Data are presented as mean ± SEM and compared 
using either paired t-tests with Bonferroni correction for multiple comparisons, one-way or two-way ANOVA with a 
Tukey multiple comparison post hoc test, as appropriate. Correlation analysis (Fig. 2J ans S2L) was performed with 
Spearman correlation test. P values < 0.05 denote statistical significance.  
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Figure legends  
 
Fig. S1. Autocrine activation of C5a receptors regulates IFN-γ production by human CD4+ T cells. (A) C5aR1 
and C5aR2 Western blot analyses on cytoplasmic (Cyt.) and membrane (Mem.) fractions of resting human CD4+ 
cells (representative of n=3). (B and C) Representative flow cytometry histograms for intracellular staining (B) and 
immunoblot with cytoplasmic (Cyt.) and membrane (Mem.) fractions (C) on C5aR1 and C5aR2 in HEK293 cells 
(HEK) transfected with a vector expressing either C5aR1, or C5aR2, or an empty control vector (Ctrl. Vec.). (D) 
Binding of radioactively-labelled 125I-C5a to HEK293 cells expressing either C5aR1, C5aR2 or no C5a receptor in 
the absence or presence of non-labelled ‘cold’ C5a as competitor (n=3). (E) IFN-γ production in CD4+ T cells 
activated for 36 hours with α-CD3 + α-CD46 in presence of increasing concentrations of exogenous C5a or 
C5adesArg (n=3), with significance assessed between untreated cells (0 ng/mL C5a or C5adesArg) and cells treated 
with indicated amounts of either C5a or C5adesArg. (F) IL-17 and IL-4 production by non-activated (NA) and 
activated (36 hours) CD4+ T cells in the absence or presence of either a C5aR1/C5aR2 double receptor antagonist 
(n=9), a C5aR2 agonist (n=8) or a C5aR1 antagonist (n=7). (G) Cell viability of T cells either resting or activated for 
36 hours as indicated in the absence or presence of the C5aR1/C5aR2 double antagonist or C5aR2 agonist (n=2). 
(H) Reduction of C5AR1 mRNA levels in T cells transfected with either a C5AR1-specific siRNA or a scrambled 
control siRNA (Ctrl. siRNA) 48 hours post transfection. Left panel shows a representative mRNA expression 
sample and the right sample statistically significant reduction in C5AR1 mRNA expression in C5AR1-specific 
siRNA-treated CD4+ T cells (n=6). Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01, ***p <0.001. 
 
Supp. Fig. 2 NLRP3 inflammasome activation occurs in CD4+ T cells and enhances IFN-γ  production. (A) 
Volcano plot showing transcripts differentially regulated in CD4+ T cells from 3 donors after α-CD3 + α-CD46 
activation (2 hours) with or without addition of the C5aR1/C5aR2 antagonist to cultures. (B) Quantitative RT-PCR 
to measure NLRP3 and IL1B mRNA in non-activated (NA) or α-CD3 + α-CD46 activated human CD4+ T cells at 36 
hours post activation (n=3, expression normalized to ACTB). (C and D) Representative NLRP3 expression assessed 
by flow cytometry (C) and by immunofluorescence (D) in non-activated naïve and memory human CD4+ T cells 
(n=3). (E and F) Representative caspase-1 and IL-1β immunoblot analyses (with lower arrows depicting the 
activated protein forms), performed on resting and α-CD3 + α-CD46 activated CD4+ T cells (36 hours) and resting 
and LPS activated monocytes (50 ng/ml, 18 hours) (representative of n=4) with densitometric analyses on activated 
caspase-1 and IL-1β in T cells. The corresponding quantitative data shown below the immunoblots do not depict 
absolute amounts of proteins in monocytes versus T cells. They depict the ratio (percentage) of non-cleaved (non-
activated) versus cleaved (activated) protein in either T cells or in monocytes.	  (G) IL-17 and IL-4 secretion in CD4+ 
cells non-activated (NA) or activated as indicated with or without the NLRP3 inhibitor MCC950 at 36 hours post 
activation (n=7). (H) Cell viability of CD4+ cells either resting or activated for 36 hours as indicated in the absence 
or presence of the NLRP3-specific inhibitor MCC950 (n=2). (I) IL-1β secretion by resting (NA) and activated CD4+ 
T cells (36 hours) with or without addition of the caspase-1 inhibitor Z-YVAD-FMK (n=4). (J) IL-18 production in 
α-CD3 + α-CD46 activated CD4+ T cells (36 hours) from three HDs (left panel) and IFN-γ production in CD4+ T 
cells from HDs 1 and 2 by T cells activated with α-CD3 + α-CD46 for 36 hours in full media and for 72 hours in 
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serum free media, in the presence of 50 µM of rIL18BP (right panel). (K) IL-1β from CD4+ T cells activated with α-
CD3 + α-CD46 for 36 hours from four healthy donors (HD1-4) and 7 patients with CAPS (P1-7). (L) Percentages of 
naïve and memory CD4+ T cell subpopulations in the blood of a second cohort of CAPS patients P8 to P14 and of 
three sex- and age-matched healthy donors (HD5-HD7). (M) Correlation between active caspase-1 and IL-1β 
production in T cells from patients P8-P14 upon CD3 + CD46 activation (Spearman correlation analysis). Error bar 
graphs represent mean ± SEM. *p <0.05, **p <0.01. 
 
Supp. Fig. 3. C5a receptors regulate NLRP3 activation to modulate IFN-γ responses. (A and B) Quantitative 
RT-PCR to measure NLRP3 (A) and IL1B mRNA (B) in resting or α-CD3 + α-CD46 activated (2 hours) human 
CD4+ T cells in the absence or presence of the C5aR1/C5aR2 antagonist with the respective corresponding bar 
graphs (panel below) showing relative expression in activated versus non-activated cells with or without 
C5aR1/C5aR2 antagonist-treated T cells (n=3, expression normalized on ACTB). (C) IL-17 and IL-4 production in 
resting or activated T cells in presence or absence of MCC950 and/or the C5aR1/C5aR2 double antagonist at 36 
hours (n=4). (D) NLRP3 expression in CD4+ T lymphocytes either left non-activated or activated with α-CD3, α-
CD3 + α-CD28 or α-CD3 + α-CD46 for 36 hours with or without addition of the C5aR1/C5aR2 antagonist (upper 
row) or the C5aR2 agonist (lower row) to cultures (data representative of n=3). (E) NLRP3 expression after α-CD3 
+ α-CD46 activation (36 hours) in T cells transfected with either C5aR1-specific siRNA or scrambled control (Ctrl.) 
siRNA (data representative of n=3). (F) IL-17 and IL-4 secretion (shown as % normalized to respective untreated 
conditions) from CD4+ T cells left non-activated (NA) or activated as indicated with or without a specific ROS 
inhibitor and/or the C5aR1/C5aR2 antagonist at 36 hours post activation (n=3). Error bar graphs represent mean ± 
SEM. *p <0.05, **p <0.01, ***p <0.001. 
 
Supp. Fig. 4 NLRP3 function in CD4+ T cells is required for optimal IFN-γ response in vivo. (A) 
Representative immunofluorescence analysis for NLRP3 and IL-1β protein expression on CD4+ T cells isolated 
from wild type (WT), Nlrp3–/– and combined Il1a–/– and Il1b–/– (Il1a/b–/–) mice. (B) Percentages of naïve and 
memory CD4+ T cells isolated from the spleen of unchallenged wild type (WT) and Nlrp3–/–, combined Il1a–/– and 
Il1b–/– (Il1a/b–/–), and Il1r1–/– mice (n=3). (C) Cell viability of sorted CD4+ T cells from WT and knock out mice 96 
hours post CD3 + CD28 activation (n=3). (D) IL-10, IL-4 and IL-17 secretion from CD4+ T cells isolated from WT 
and knock out mice activated 96 hours with antibodies to CD3 and CD28 (n=3). (E) Cell viability of sorted CD4+ T 
cells from WT and Nlrp3–/– mice assessed with or without MCC950 addition (right panel) during activation (96 
hours post α-CD3 + α-CD28 activation, n=4). (F) IL-10, IL-4 and IL-17 secretion from CD4+ T cells activated 96 
hours with antibodies to CD3 and CD28 from WT and Nlrp3–/–mice with or without addition of MCC950 (n=4). (G 
and H) IFN-γ, IL-10, IL-4 and IL-17 secretion from sorted naïve (G) and memory (H) CD4+ T cells from WT, 
Nlrp3–/–, Il1a/b–/–, and Il1r1–/– mice 96 hours post α-CD3 + α-CD28 activation (n=3). Error bar graphs represent 
mean ± SEM. *p <0.05. 
Supp. Fig. 5 Lack of intrinsic NLRP3 inflammasome function in CD4+ T cells impacts on GvHD disease. (A-
D) Disease scores and Th1 and Th17 T cell populations. T cell-depleted C57BL/6 bone marrow was transferred into 
lethally irradiated BALB/c mice alone (control group), or with the addition of 1 x 106 naïve CD4+ T cell from either 
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C57BL/6 or Nlpr3–/– mice. (A) Colon length at study endpoint (12 days post-cell transfer). (B-D) Intracellular IFN-γ 
and IL-17A staining of mesenteric lymph node CD4+ T cells at the study endpoint after overnight α-CD3 and α-CD28 
stimulation and brefeldin A and monensin addition for 5 hours (Gated on live CD4+ Thy1.2+ C57BL/6 (H-2KdDd+) T 
cells). Percent (B) and mean fluorescence intensity (MFI) of IFN-γ+ cells (C) and percent IL-17A+ cells (D). For (A-D) 
n=4 WT, 5 KO, 2 controls. (E) In vitro cytokine production of CD4+ T cells from wild type and C5ar2–/– mice with or 
without addition of MCC950 at 48 hours post α-CD3 + α-CD28 activation. Error bar graphs represent mean ± SEM. 
*p <0.05, **p <0.01, ***p <0.001. 
 
Supp. Fig. 6 The C5aR2-NLRP3-IL-1β axis may regulate ‘IL-10 switching’ in human Th1 cells. (A) Suggested 
model of complement-regulated inflammasome activation during Th1 responses: TCR stimulation together with 
CD46 (via autocrine C3b generation, not shown) engagement triggers intracellular C5 activation and C5a 
generation. Subsequent intracellular C5aR1 engagement mediates ROS production and NLRP3 assembly which in 
turn induces caspase-1-mediated IL-1β maturation. Autocrine IL-1β function promotes IFN-γ production and Th1 
induction but restricts ‘IL-10 switching’ (at least in human CD4+ T cells). C5aR2 cell surface activation by secreted 
C5a (or C5adesArg) negatively controls these events (either via direct inhibition of C5aR1 activation and/or other 
yet undefined mechanisms) thereby allowing for IL-10 co-induction during Th1 contraction. It is currently unclear 
whether intracellular C5aR2 activation occurs and what the potential role of such stimulation could be. (B) IFN-γ to 
IL-10 ratio in α-CD3 + α-CD28 or α-CD3 + α-CD46 activated (36 hours) CD4+ T cells in the absence or presence of 
either a C5aR1/C5aR2 double receptor antagonist (n=9), a C5aR2 agonist (n=8) or a C5aR1 antagonist (n=7). (C) 
IL-10 production by resting and activated CD4+ T cells, in presence or absence of MCC950 and/or rhIL-1β 
measured at 36 hours post activation (n=3). (D) IL-10 secretion at 36 hours post indicated activation by CD4+ cells 
from the patients with CAPS P8-P14 and seven sex- and age-matched healthy donors (HD5-11) with data 
represented as mean ± SEM. Error bar graphs represent mean ± SEM. *p <0.05, **p <0.01. 
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Table S1. 
Normalized read values from microarrays for Fig. 2A and B  
Table is provided in Other Supplementary Material as an Excel file.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
ID p-value Fold change 
C15orf48 0.0118739 2.08331 
C3orf14 0.0327513 2.13952 
CXCL2 0.0330927 5.59906 
DDX60 0.00208813 2.38253 
DTX3L 0.0101958 2.02692 
EIF2AK2 0.00659247 3.45509 
EREG 0.00093681 2.50735 
FAM45B 0.035722 2.16729 
HERC6 0.00197424 2.8311 
HSH2D 0.0219705 2.13182 
IFI44 0.00790994 2.89407 
IFI44L 0.0204978 4.5496 
IFIH1 0.00489751 2.63568 
IFIT1 0.0250406 3.36767 
IFIT3 0.0192085 4.57257 
IFIT5 0.00982865 2.10946 
IL1A 0.0137544 3.52362 
IL1B 0.0053077 2.36807 
IL6 0.0145825 3.11426 
IL8 0.00751255 3.61565 
LAMP3 0.0046064 2.25455 
MX1 0.032786 4.21644 
NM_001199779 
// PSMB2  0.0148295 -2.09297 
OAS2 0.010885 4.16812 
OR4N2 0.0348681 -2.69263 
PARP9 0.0314253 3.3435 
PTGS2 0.00566655 3.80875 
SAMD9 0.0116602 2.07468 
SAMD9L 0.0364514 3.18497 
SERPINB2 0.0268882 3.68178 
TNFAIP6 0.0045844 2.61021 
Table S2. 
Genes differentially regulated by the C5aR1/C5aR2 double antagonist  
Reported the p-value and the fold change (α-CD3 + α-CD46 + C5aR1/C5aR2 double antagonist vs α-CD3 + α-
CD46) 
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Patient 
N
o
 
Age/gender  NLRP3 Mutation Treatment 
1 59 y./female V198M Canakinumab 
2 29 y./female V198M Canakinumab 
3 45 y./male T436I Anakinra 
4 53 y./male 
mut neg (mosaic c.1699G>A, E567K, 
in 5.2% of cells) Anakinra 
5 72 y./male A439V Canakinumab 
6 22 y./male R260W Canakinumab 
7 16 y./male R260W Canakinumab 
 
Table S3. 
Details of seven patients (1 to 7) with cryopyrin-associated periodic syndrome (CAPS) 
 
 
 
Patient 
N
o
 
Age/gender  NLRP3 Mutation Treatment 
8 31 y./female A439V Canakinumab 
9 52 y./female A439V Canakinumab 
10 29 y./female A439V Canakinumab 
11 55 y./female A439V Canakinumab 
12 27 y./female A439V Starting canakinumab 
13 60 y./female A439V Starting canakinumab 
14 67 y./female somatic mosaicism (none in germline) On anakinra for 3 weeks 
Table S4. 
Details of seven patients (8 to 14) with cryopyrin-associated periodic syndrome (CAPS) and A439V mutation 
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Gene Primer Forward Primer Reverse 
 
C5AR1 5'-CACTAGGGCCCAGAAGAC-3’ 5'-AAGAGTCCCGCTGGAAAAGG-3’ 
 
C5AR2 5’-GCTCTTCCTGTATTTTGGGAGGG-3’ 5’-GCTGGTGGATTTCTTGCTGTCC-3’ 
 
NLRP3 5’-GGCAACACTCTCGGAGACAAG-3’ 5’-GCTCTGGCTGGAGGTCAGAA-3’ 
 
IL1B 5'-CTCGCCAGTGAAATGATGGCT-3' 5'-GTCGGAGATTCGTAGCTGGAT-3' 
 
ACTB 5'-ACGGCCAGGTCATCACCATTG-3' 5'-AGTTTCGTGGATGCCACAGGAC-3' 
 
Nlrp3 5’-AGCCAGAGTGGAATGACACG-3’ 5’-CGTGTAGCGACTGTTGAGGT-3’ 
 
Il1b 5’-ATCAACCAACAAGTGATATTCTCCAT-3’ 5’-GGGTGTGCCGTCTTTCATTAC-3’ 
 
Il1r1 5’-ATGGAAGTCTTGTGTGCCCT-3’ 5’-TCCGAAGAAGCTCACGTTGT-3’ 
 
Actb 5’-GATGCCCTGAGGCTCTTTTCC-3’ 5’-GAGGTCTTTACGGATGTCAACGTCA-3’ 
 
 
Table S5. 
Listed primers sequences 
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Fig. S2 
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Fig. S3 
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Fig. S4 
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Fig. S5 
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Fig. S6 
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